Real-World Treatment Duration With First-line Enfortumab Vedotin Plus Pembrolizumab for Advanced Urothelial Cancer: A National Electronic Health Record Study. (PubMed, Clin Genitourin Cancer) - Sep 12, 2026 - "In this large US cohort of primarily cisplatin-ineligible patients, rwToT with first-line EV+P approximated that observed in clinical trials, though modestly shorter. These findings likely reflect the greater clinical frailty of patients treated in routine practice. Continued follow-up will be needed to evaluate long-term outcomes and treatment sequencing following EV+P adoption."
HEOR • Journal • Real-world evidence • Genito-urinary Cancer • Oncology • Solid Tumor • Urothelial Cancer
|
|
Aram Babcock; Blanca Homet Moreno; Chethan Ramamurthy; Ernesto Ulloa-Pérez; Haojie Li; Melanie Mayer; Nicholas J Seewald; Ronac Mamtani
|